Nebuliser, inhaler demand for children jumps by up to 60 pc in Delhi winters: Survey

New Delhi:  The demand for nebulisers, inhalers and respiratory medicines for children has surged sharply in Delhi during winter months, with chemists reporting spikes of up to 60 per cent during periods of severe air pollution, a survey has found out.

Nearly one-third of all nebuliser purchases were for children, reflecting the growing respiratory distress among younger age groups amid worsening air quality, the survey report noted.

The comprehensive survey was carried out by ‘Warrior Moms’ in collaboration with chemists in south, east, north and central Delhi last year, followed by a re-run with more pharmacists this year.

Chemists reported that sales of commonly prescribed asthma and respiratory medicines such as Asthalin, Levolin, Budecort and Seroflo rose significantly between November and January, when pollution levels typically peak.

In north Delhi alone, sales of some inhalers increased by about 40 per cent, while central and south Delhi outlets recorded a 50 to 60 per cent jump in demand for nebulisers.

Parents frequently complained of symptoms such as persistent cough, wheezing, breathlessness and chest tightness in children, with many chemists noting that these problems worsened during high-smog periods, especially in the early mornings and evenings, the survey said.

The report also highlighted supply challenges, with several pharmacies struggling to maintain stocks of high-demand items like Duolin Respules and Budecort nebulising solutions during peak pollution months.

Calling the findings a public health warning, the survey recommended advance stocking of respiratory aids, improved supply chain management and greater public awareness, particularly in schools, to help parents and children cope with pollution-related respiratory illnesses during Delhi’s winter season.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction